Clinical Trial: Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06792799) titled 'Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease' on Jan. 20.

Brief Summary: this is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.

Study Start Date: Jan. 30

Study Type: INTERVENTIONAL

Condition: Autoimmune Diseases Systemic Lupus Erthematosus Multi-Drug Resistant Nephrotic Syndrome

Intervention: BIOLOGICAL: anti-CD19/BCMA CAR NK cells (KN5601)

Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD1...